{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:48:48Z","timestamp":1789541328256,"version":"build-2803163510"},"reference-count":97,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.dld.2025.12.017","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T20:19:39Z","timestamp":1769631579000},"page":"297-307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["AISF-SIMIT practice guidance on treatment of hepatitis d virus (HDV): A 2025 update"],"prefix":"10.1016","volume":"58","author":[{"given":"Elisabetta","family":"Degasperi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonietta","family":"Pisaturo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Aghemo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Andreoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizia","family":"Brunetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenza","family":"Calvaruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Ciancio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"D\u2019Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpiero","family":"D\u2019Offizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni B.","family":"Gaeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Lampertico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio M.","family":"Mastroianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia Anna","family":"Niro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Parrella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Puoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Paolo","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Santantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Toniutto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Vigan\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2025.12.017_bib0001","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2023.05.001","article-title":"EASL Clinical Practice Guidelines on hepatitis delta virus","volume":"79","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.12.017_bib0002","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"83","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.12.017_bib0003","unstructured":"Aghemo A, Andreoni M, Gaeta GB, Geretti AM, Lampertico P, Mastroianni CM, Svicher V. Indicazioni operative AISF e SIMIT per la diagnosi e la gestione clinica del paziente affetto da epatite Delta. https:\/\/www.webaisf.org\/wp-content\/uploads\/2023\/03\/documento-aisf-simit_140323.pdf."},{"key":"10.1016\/j.dld.2025.12.017_bib0004","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of Hepatitis D Virus infection: Systematic review and meta-analysis","volume":"73","author":"Stockdale","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.12.017_bib0005","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1093\/infdis\/jiz633","article-title":"Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection","volume":"221","author":"Miao","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.dld.2025.12.017_bib0006","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1136\/gutjnl-2018-316601","article-title":"Prevalence and burden of Hepatitis D Virus infection in the global population: a systematic review and meta-analysis","volume":"68","author":"Chen","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.dld.2025.12.017_bib0007","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jhep.2023.10.043","article-title":"Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories","volume":"80","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.12.017_bib0008","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70336","article-title":"Diagnosed patients with Chronic Hepatitis B and Delta virus in Italy in 2024: an estimation from a national real-world database","volume":"45","author":"Loglio","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2025.12.017_bib0009","article-title":"Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D","volume":"4","author":"Palom","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.dld.2025.12.017_bib0010","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/liv.15746","article-title":"Anti-HDV reflex testing in HBsAg-positive subjects: An efficacious strategy to identify HDV infection","volume":"44","author":"Cossiga","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2025.12.017_bib0011","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jhep.2023.02.041","article-title":"Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV\/HDV-prevalence countries","volume":"79","author":"Razavi","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.12.017_bib0012","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/apt.17878","article-title":"Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection","volume":"59","author":"Sandmann","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2025.12.017_bib0013","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.cgh.2024.08.008","article-title":"High Diagnostic Value of Transient Elastography for Advanced Fibrosis and Cirrhosis in Patients With Chronic Hepatitis Delta","volume":"23","author":"Roulot","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.dld.2025.12.017_bib0014","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1097\/HEP.0000000000000642","article-title":"Association of hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis","volume":"79","author":"Gish","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2025.12.017_bib0015","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/apt.15521","article-title":"Long-term clinical outcomes in patients with chronic hepatitis delta: the role of persistent viraemia","volume":"51","author":"Palom","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2025.12.017_bib0016","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jhep.2020.06.038","article-title":"Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta","volume":"73","author":"Roulot","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.12.017_bib0017","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1053\/j.gastro.2004.03.017","article-title":"Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis","volume":"126","author":"Farci","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2025.12.017_bib0018","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jhep.2018.12.022","article-title":"Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy","volume":"70","author":"Yurdaydin","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.12.017_bib0019","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jhep.2023.06.002","article-title":"2022 AASLD-EASL HBV-HDV Treatment endpoints conference faculty. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: report from the 2022 AASLD-EASL HBV-HDV treatment endpoints conference","volume":"79","author":"Ghany","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.12.017_bib0020","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S0168-8278(25)00313-7","article-title":"Final results of MYR301: a randomized phase 3 study evaluating the efficacy and safety of up to 144 weeks of bulevirtide monotherapy for chronic hepatitis delta and 96 weeks of posttreatment follow-up","volume":"82","author":"Wedemeyer","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.12.017_bib0021","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/S0168-8278(25)00381-2","article-title":"Predictors of undetectable hepatitis delta virus RNA at 48 weeks after end of treatment with Bulevirtide monotherapy in the MYR 301 study","volume":"82","author":"Aleman","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.12.017_bib0022","doi-asserted-by":"crossref","first-page":"S802","DOI":"10.1016\/S0168-8278(24)02220-7","article-title":"Sustained virological response after treatment with Bulevirtide in HDV patients. Data from the french multicenter real-life cohort","volume":"80","author":"de L\u00e9dinghen","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.12.017_bib0023","doi-asserted-by":"crossref","first-page":"S812","DOI":"10.1016\/S0168-8278(25)02097-5","article-title":"HBV reactivation in HBV\/HDV coinfected patients during bulevirtide monotreatment","volume":"82","author":"Killer","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.12.017_bib0024","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jhep.2022.05.023","article-title":"Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread","volume":"77","author":"Zhang","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.12.017_bib0025","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.21296","article-title":"Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta","volume":"44","author":"Niro","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2025.12.017_bib0026","first-page":"1648","article-title":"Pegylated interferon alfa-2b for chronic delta hepatitis: 12 versus 24 months","volume":"58","author":"Ormeci","year":"2011","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.dld.2025.12.017_bib0027","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa0912696","article-title":"Peginterferon plus adefovir versus either drug alone for hepatitis delta","volume":"364","author":"Wedemeyer","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2025.12.017_bib0028","doi-asserted-by":"crossref","first-page":"625","DOI":"10.4254\/wjh.v8.i14.625","article-title":"Co-treatment with pegylated interferon alfa-2a and entecavir for hepatitis D: A randomized trial","volume":"8","author":"Abbas","year":"2016","journal-title":"World J Hepatol"},{"key":"10.1016\/j.dld.2025.12.017_bib0029","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1473-3099(18)30663-7","article-title":"Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomized, placebo controlled, phase 2 trial","volume":"19","author":"Wedemeyer","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.dld.2025.12.017_bib0030","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1097\/HEP.0000000000000309","article-title":"Treatment of chronic hepatitis D with peginterferon lambda-the phase 2 LIMT-1 clinical trial","volume":"77","author":"Etzion","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2025.12.017_bib0031","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/liv.15745","article-title":"Five-year follow-up of 96\u2009weeks peginterferon plus tenofovir disoproxil fumarate in hepatitis D","volume":"44","author":"Anastasiou","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2025.12.017_bib0032","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/hep.21325","article-title":"Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up","volume":"44","author":"Castelnau","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2025.12.017_bib0033","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/j.1478-3231.2006.01279.x","article-title":"Treatment of chronic hepatitis delta with pegylated interferon-alpha2b","volume":"26","author":"Erhardt","year":"2006","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2025.12.017_bib0034","first-page":"377","article-title":"Weight-based dosing regimen of peg-interferon \u03b1-2b for chronic hepatitis delta: a multicenter Romanian trial","volume":"20","author":"Gheorghe","year":"2011","journal-title":"J Gastrointestin Liver Dis"},{"key":"10.1016\/j.dld.2025.12.017_bib0035","doi-asserted-by":"crossref","first-page":"731","DOI":"10.5812\/kowsar.1735143X.2462","article-title":"Treatment of chronic delta hepatitis: a nine-year retrospective analysis","volume":"11","author":"Gulsun","year":"2011","journal-title":"HepatMon"},{"key":"10.1016\/j.dld.2025.12.017_bib0036","first-page":"561","article-title":"Efficacy of pegylated interferon-\u03b1 treatment for 24 months in chronic delta hepatitis and predictors of response","volume":"18","author":"Karaca","year":"2013","journal-title":"AntivirTher"},{"key":"10.1016\/j.dld.2025.12.017_bib0037","first-page":"463","article-title":"Treatment of chronic hepatitis D patients with pegylated interferon: a real-world experience","volume":"19","author":"Abbas","year":"2014","journal-title":"AntivirTher"},{"key":"10.1016\/j.dld.2025.12.017_bib0038","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/apt.12788","article-title":"Long-term therapy of chronic delta hepatitis with peginterferon alfa","volume":"40","author":"Heller","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2025.12.017_bib0039","doi-asserted-by":"crossref","DOI":"10.5812\/hepatmon.15729","article-title":"Interferon alpha-2b therapy in chronic hepatitis delta","volume":"14","author":"Keshvari","year":"2014","journal-title":"HepatMon"},{"key":"10.1016\/j.dld.2025.12.017_bib0040","doi-asserted-by":"crossref","DOI":"10.5812\/hepatmon.24366","article-title":"Pegylated Interferon \u03b1 therapy in chronic Delta hepatitis: a one-center experience","volume":"15","author":"Bahcecioglu","year":"2015","journal-title":"Hepat Mon"},{"key":"10.1016\/j.dld.2025.12.017_bib0041","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1080\/00325481.2016.1175310","article-title":"Comparison of the efficacy of 12 months and longer courses of interferon therapy for the treatment of chronic delta hepatitis: a retrospective cohort study","volume":"128","author":"Soyer","year":"2016","journal-title":"Postgrad Med"},{"key":"10.1016\/j.dld.2025.12.017_bib0042","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijid.2016.03.017","article-title":"Treatment of hepatitis delta virus genotype 3 infection with peg-interferon and entecavir","volume":"46","author":"Borzacov","year":"2016","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.dld.2025.12.017_bib0043","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/hep.28876","article-title":"Antiviral treatment and liver-related complications in hepatitis delta","volume":"65","author":"Wranke","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2025.12.017_bib0044","first-page":"1329","article-title":"Antiviral treatment with pegylated interferon and clinical outcomes in a cohort of immigrants patients affected by hepatitis delta: A retrospective analysis","volume":"91","author":"Boglione","year":"2019","journal-title":"J MedVirol"},{"key":"10.1016\/j.dld.2025.12.017_bib0045","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3390\/tropicalmed9040073","article-title":"Results of response-guided therapy with Pegylated Interferon alpha 2a in chronic hepatitis B and D","volume":"9","author":"Gherlan","year":"2024","journal-title":"Trop Med Infect Dis"},{"key":"10.1016\/j.dld.2025.12.017_bib0046","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/liv.14740","article-title":"Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study","volume":"41","author":"Bremer","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2025.12.017_bib0047","series-title":"Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta","year":"2023"},{"key":"10.1016\/j.dld.2025.12.017_bib0048","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016","article-title":"Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib\/IIa study","volume":"65","author":"Bogomolov","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.12.017_bib0049","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1473-3099(22)00318-8","article-title":"Safety and efficacy of Bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomized, parallel-group, open-label, phase 2 trial","volume":"23","author":"Wedemeyer","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.dld.2025.12.017_bib0050","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70008","article-title":"Phase 2 randomized study of Bulevirtide as monotherapy or combined with Peg-IFN\u03b1-2a as treatment for chronic hepatitis Delta","volume":"45","author":"Lampertico","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2025.12.017_bib0051","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1056\/NEJMoa2314134","article-title":"Bulevirtide combined with Pegylated Interferon for chronic hepatitis D","volume":"391","author":"Asselah","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2025.12.017_bib0052","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa2213429","article-title":"A Phase 3, randomized trial of Bulevirtide in chronic hepatitis D","volume":"389","author":"Wedemeyer","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2025.12.017_bib0053","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jhep.2024.05.001","article-title":"Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial","volume":"81","author":"Wedemeyer","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.12.017_bib0054","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1016\/S0168-8278(24)00596-8","article-title":"Efficacy and safety of 144 weeks of Bulevirtide 2 mg or 10 mg monotherapy from the ongoing phase 3 study, MYR301","volume":"80","author":"Lampertico","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.12.017_bib0055","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3390\/v17020251","article-title":"Assessment of response and safety of Bulevirtide treatment in patients with chronic Delta virus infection: the ARISTOTLE pilot observational study","volume":"17","author":"Rinaldi","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.dld.2025.12.017_bib0056","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3390\/pathogens11050517","article-title":"Efficacy and safety of Bulevirtide plus Tenofovir Disoproxil Fumarate in real-world patients with chronic hepatitis B and D co-infection","volume":"11","author":"Herta","year":"2022","journal-title":"Pathogens"},{"key":"10.1016\/j.dld.2025.12.017_bib0057","article-title":"Treating hepatitis D with Bulevirtide - Real-world experience from 114 patients","volume":"5","author":"Dietz-Fricke","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.dld.2025.12.017_bib0058","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1111\/liv.15408","article-title":"Real-life experiences with Bulevirtide for the treatment of hepatitis delta-48 weeks data from a German centre","volume":"42","author":"Z\u00f6llner","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2025.12.017_bib0059","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jhep.2022.07.016","article-title":"Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension","volume":"77","author":"Degasperi","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.12.017_bib0060","first-page":"S221","article-title":"Efficacy and safety of treatment with Bulevirtide in chronic hepatitis delta: primary results of the real-life ANRS HDEP01 BULEDELTA cohort","volume":"76","author":"Zoulim","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2025.12.017_bib0061","first-page":"S26","article-title":"Bulevirtide with or without Peg-Interferon in HDV infected patients in a real-life setting. Two-year results from the French multicenter early access program","volume":"76","author":"De Ledinghen","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2025.12.017_bib0062","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/apt.16945","article-title":"Response-guided long-term treatment of chronic hepatitis D patients with Bulevirtide-results of a \"real world\" study","volume":"56","author":"Jachs","year":"2022","journal-title":"Aliment PharmacolTher."},{"key":"10.1016\/j.dld.2025.12.017_bib0063","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.dld.2025.01.030","article-title":"Bulevirtide for patients with chronic Hepatitis D (CHD) in Italy: a multicenter prospective nationwide real-life study (D-Shield)","volume":"57","author":"Anolli","year":"2025","journal-title":"Digestive and Liver Disease"},{"key":"10.1016\/j.dld.2025.12.017_bib0064","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jhep.2024.12.044","article-title":"Real-world effectiveness and safety of Bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis","volume":"82","author":"Degasperi","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.12.017_bib0065","article-title":"Long-term treatment with Bulevirtide in patients with chronic hepatitis D and advanced chronic liver disease","volume":"2024","author":"Sapuk","year":"2024","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2025.12.017_bib0066","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jhep.2021.10.012","article-title":"Safety and effectiveness of up to 3 years' Bulevirtide monotherapy in patients with HDV-related cirrhosis","volume":"76","author":"Loglio","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.12.017_bib0067","doi-asserted-by":"crossref","first-page":"S810","DOI":"10.1016\/S0168-8278(25)02093-8","article-title":"Virological outcomes in patients with HDV-related compensated cirrhosis treated with Bulevirtide monotherapy for 144 weeks: a sub analysis of the retrospective multicenter European study (Save-D)","volume":"82","author":"Degasperi","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.12.017_bib0068","doi-asserted-by":"crossref","first-page":"S814","DOI":"10.1016\/S0168-8278(25)02100-2","article-title":"Low risk of decompensation and HCC in patients with HDV- related compensated cirrhosis treated with Bulevirtide monotherapy for up to 144 weeks: the retrospective multicenter European study (Save-D)","volume":"82","author":"Degasperi","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.12.017_bib0069","first-page":"S823","article-title":"Pharmacokinetics, pharmacodynamics, and safety of bulevirtide 2 mg once-daily for 6 days in participants with moderate and severe hepatic impairment and in matched control participants with normal hepatic function","volume":"82","author":"Kumar","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.12.017_bib0070","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1097\/HEP.0000000000000847","article-title":"Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis-A real-world case series","volume":"80","author":"Dietz-Fricke","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2025.12.017_bib0071","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70033","article-title":"Bulevirtide in Chronic Hepatitis D Patients Awaiting Liver Transplantation results from a French multicentric retrospective study","volume":"45","author":"Meszaros","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2025.12.017_bib0072","first-page":"254","article-title":"Bulevirtide improves liver function in candidates for liver transplant with advanced HDV cirrhosis and severe portal hypertension","volume":"31","author":"Loglio","year":"2025","journal-title":"LiverTranspl"},{"key":"10.1016\/j.dld.2025.12.017_bib0073","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jhep.2008.05.029","article-title":"Complete cure of HBV-HDV co-infection after 24weeks of combination therapy with pegylated interferon and ribavirin in a patient co-infected with HBV\/HCV\/HDV\/HIV","volume":"50","author":"Gozlan","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.12.017_bib0074","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0168-8278(98)80177-3","article-title":"Treatment of chronic hepatitis D with interferon alpha-2b in patients with human immunodeficiency virus infection","volume":"29","author":"Puoti","year":"1998","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.12.017_bib0075","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1089\/aid.2013.0008","article-title":"Effect of tenofovir with and without interferon on hepatitis D virus replication in HIV-hepatitis B virus-hepatitis D virus-infected patients","volume":"29","author":"Boyd","year":"2013","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.dld.2025.12.017_bib0076","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/hiv.13518","article-title":"Real world\" efficacy of bulevirtide in HBV\/HDV-related cirrhosis including people living with HIV: Results from the compassionate use programme at INMI Spallanzani in Rome, Italy","volume":"24","author":"Visco Comandini","year":"2023","journal-title":"HIV Med"},{"key":"10.1016\/j.dld.2025.12.017_bib0077","article-title":"Treatment with bulevirtide in HIV-infected patients with chronic hepatitis D: ANRS HD EP01 BuleDelta and compassionate cohort","volume":"6","author":"deL\u00e9dinghen","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.dld.2025.12.017_bib0078","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1016\/j.jhep.2023.11.019","article-title":"Increase in HDV replication during steroid therapy - potential implications for testing and treatment strategies","volume":"81","author":"Patmore","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.12.017_bib0079","first-page":"810","article-title":"Bulevirtide treatment of hepatitis Delta virus infection in a kidney transplant recipient: a case report","volume":"22","author":"Pinchera","year":"2024","journal-title":"Exp Clin Transplant"},{"key":"10.1016\/j.dld.2025.12.017_bib0080","first-page":"S151","article-title":"Pharmacokinetis, pharmacodynamics, and safety of Bulevirtide 2 mg once dailiy for 6 days in participants with severe renal impairment and in matched controls participant with normal renal function","volume":"80","author":"Wang","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2025.12.017_bib0081","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.dld.2025.01.046","article-title":"Hepatitis Delta virus (HDV) replication through HBV integrants in HCC recurrence after liver transplantation","volume":"57","author":"Di Marco","year":"2025","journal-title":"Digestive and Liver Disease"},{"key":"10.1016\/j.dld.2025.12.017_bib0082","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1016\/j.cgh.2015.05.029","article-title":"Association between level of hepatitis D virus RNA at week 24 of pegylated interferon therapy and outcome","volume":"13","author":"Keskin","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2025.12.017_bib0083","first-page":"620","article-title":"HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response","volume":"44","author":"Niro","year":"2016","journal-title":"AlimentPharmacolTher"},{"key":"10.1016\/j.dld.2025.12.017_bib0084","article-title":"Long-term follow-up of patients discontinuing Bulevirtide treatment upon long-term HDV-RNA suppression","volume":"5","author":"Jachs","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.dld.2025.12.017_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2022.12.023","article-title":"A 3-year course of Bulevirtide monotherapy may cure HDV infection in cirrhotics","author":"Anolli","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.12.017_bib0086","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3390\/pharmaceutics17020250","article-title":"Clinical pharmacology of Bulevirtide: focus on known and potential drug-drug interactions","volume":"17","author":"Billi","year":"2025","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.dld.2025.12.017_bib0087","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2025.105850","article-title":"Comparison of diagnostic performances of HDV-RNA quantification assays used in clinical practice: Results from a national quality control multicenter study","volume":"180","author":"Salpini","year":"2025","journal-title":"J Clin Virol"},{"key":"10.1016\/j.dld.2025.12.017_bib0088","article-title":"Comparing methods for plasma HDV RNA quantification in bulevirtide-treated and untreated patients with HDV","volume":"7","author":"Anolli","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.dld.2025.12.017_bib0089","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/HEP.0000000000000584","article-title":"HDV RNA assays: Performance characteristics, clinical utility, and challenges","volume":"81","author":"Wedemeyer","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2025.12.017_bib0090","doi-asserted-by":"crossref","first-page":"E32","DOI":"10.1097\/HEP.0000000000000975","article-title":"Letter to the Editor: The WHO HDV RNA international standard does not reflect variability of real-world samples","volume":"81","author":"Sandmann","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2025.12.017_bib0091","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/gutjnl-2023-330644","article-title":"Quantification of circulating HBV RNA expressed from intrahepatic cccDNA in untreated and NUC treated patients with chronic hepatitis B","volume":"73","author":"Testoni","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.dld.2025.12.017_bib0092","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/hep.30325","article-title":"Serum Hepatitis B Virus RNA: A New Potential Biomarker for Chronic Hepatitis B Virus Infection","volume":"69","author":"Liu","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2025.12.017_bib0093","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.jhep.2024.11.051","article-title":"Differential HBV RNA and HBcrAg patterns in untreated patients with chronic hepatitis delta","volume":"82","author":"Degasperi","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2025.12.017_bib0094","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70003","article-title":"Value and Kinetics of Virological Markers in the Natural Course of Chronic Hepatitis D Virus Infection","volume":"45","author":"Sandmann","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2025.12.017_bib0095","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/hep4.1821","article-title":"HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta","volume":"6","author":"Sandmann","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.dld.2025.12.017_bib0096","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/jvh.13804","article-title":"Kinetics and predictive value of HBcrAg, HBV RNA and anti-HBc during bulevirtide treatment of chronic HDV-infected patients","volume":"30","author":"Sandmann","year":"2023","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.dld.2025.12.017_bib0097","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70094","article-title":"HBsAg Isoforms as Innovative Biomarkers in Predicting Virological Response to Bulevirtide in Patients With Chronic Hepatitis D","volume":"45","author":"D'Anna","year":"2025","journal-title":"Liver Int"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865825012575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865825012575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T12:27:59Z","timestamp":1771504079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865825012575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":97,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1590865825012575"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2025.12.017","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AISF-SIMIT practice guidance on treatment of hepatitis d virus (HDV): A 2025 update","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2025.12.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}